Article Sidebar
Main Article Content
The Role of Pancreatic Enzyme Insufficiency in the Etiology of Functional Dyspepsia Resistant to Standard Treatment
Main Article Content
Abstract
Background/Aims: Functional dyspepsia (FD) is diagnosed in the absence of an identifiable organic cause. Pancreatic enzyme insufficiency (PEI) remains an underrecognized condition in these patients. This study aimed to investigate the prevalence of PEI among FD patients unresponsive to standard therapy and to evaluate its clinical and biochemical characteristics.
Materials and Methods: A total of 154 patients diagnosed with FD were followed, among which 66 patients who did not respond to at least 4 weeks of standard treatment, including acid-reducing therapies, prokinetics, and antidepressants, were evaluated. Additionally, 34 healthy volunteers were included as a control group. Organic pathologies were excluded in all 66 patients with FD resistant to standard treatment using endoscopy, endoscopic biopsy, and imaging methods. Fecal elastase-1 (FE-1) enzyme levels were measured to determine the prevalence of PEI in both groups.
Results: Pancreatic enzyme insufficiency was detected in 5 (7.57%) of the 66 treatment-resistant FD patients, while none of the controls had PEI. The prevalence of PEI was significantly higher in diabetic patients than in non-diabetic patients within the study group (P = .037). Patients with diarrhea, sticky stools, and frequent foul-smelling stools exhibited a higher prevalence of PEI (P = .022, P = .001, and P = .004, respectively). In the study group, PEI patients had lower serum calcium, phosphorus, and magnesium levels than the control group (P = .018, P = .011, and P = .001, respectively).
Conclusion: Pancreatic enzyme insufficiency was identified in 7.57% of patients resistant to standard treatment. In patients resistant to standard therapy for at least 4 weeks, the presence of symptoms such as diarrhea, sticky stools, and foul-smelling stools, along with diabetes mellitus and low serum calcium, phosphorus, and magnesium levels, may warrant consideration of PEI as a potential underlying condition
Cite this article as: Kemik F, Ceylan G, Aydin AF, et al. The role of pancreatic enzyme insufficiency in the etiology of functional dyspepsia resistant to standard treatment. Turk J Gastroenterol. 2025;36(7):467-473.
Article Details
References
1. Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and
risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut.
2015;64(7):1049-1057. [CrossRef]
2.Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional
dyspepsia. Lancet. 2020;396(10263):1689-1702. [CrossRef]
3.Fujikawa Y, Tominaga K, Tanaka F, et al. Postprandial symptoms
felt at the lower part of the epigastrium and a possible association
of pancreatic exocrine dysfunction with the pathogenesis of functional dyspepsia. Intern Med. 2017;56(13):1629-1635. [CrossRef]
4.Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013;19(42):7258-7266. [CrossRef]
5.Struyvenberg MR, Martin CR, Freedman SD. Practical guide to exocrine pancreatic insufficiency–breaking the myths. BMC Med.
2017;15(1):29. [CrossRef]
6.Tahtacı M, Algın O, Karakan T, et al. Can pancreatic steatosis
affect exocrine functions of pancreas? Turk J Gastroenterol.
2018;29(5):588-594. [CrossRef]
7.Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG.
Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129-139. [CrossRef]
8.Hart PA, Conwell DL. Diagnosis of exocrine pancreatic insufficiency. Curr Treat Options Gastroenterol. 2015;13(3):347-353.
[CrossRef]
9.Vanga RR, Tansel A, Sidiq S, El-Serag HB, Othman MO. Diagnostic
performance of measurement of fecal elastase-1 in detection of
exocrine pancreatic insufficiency: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(8):1220-1228.e4.
[CrossRef]
10. Stein J, Jung M, Sziegoleit A, Zeuzem S, Caspary WF, Lembcke B.
Immunoreactive elastase I: clinical evaluation of a new noninvasive
test of pancreatic function. Clin Chem. 1996;42(2):222-226.
[CrossRef]
11. Simren M, Palsson OS, Whitehead WE. Update on Rome IV criteria
for colorectal disorders: implications for clinical practice. Curr Gastroenterol Rep. 2017;19(4):15. [CrossRef]
12. Fraser A, Delaney BC, Ford AC, Qume M, Moayyedi P. The shortform leeds dyspepsia questionnaire validation study. Aliment Pharmacol Ther. 2007;25(4):477-486. [CrossRef]
13. Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW,
Vakil N. ACG and CAG clinical guideline: management of dyspepsia.
Am J Gastroenterol. 2017;112(7):988-1013. [CrossRef]
14. Bytzer P, Talley NJ. Dyspepsia. Ann Intern Med. 2001;134(9 Pt
2):815-822. [CrossRef]
15. Jung HK, Keum BR, Jo YJ, et al. Diagnosis of functional dyspepsia:
a systematic review. Korean J Gastroenterol. 2010;55(5):296-307.
[CrossRef]
16. Enck P, Azpiroz F, Boeckxstaens G, et al. Functional dyspepsia.
Nat Rev Dis Primers. 2017;3(1):17081. [CrossRef]
17. Miwa H, Oshima T, Tomita T, et al. Recent understanding of the
pathophysiology of functional dyspepsia: role of the duodenum as
the pathogenic center. J Gastroenterol. 2019;54(4):305-311.
[CrossRef]
18. Worning H. Exocrine pancreatic function in dyspepsia. Digestion.
1987;37(Suppl 1):3-13. [CrossRef]
19. Skude G, Andrén P, Hallert C, et al. Pancreatic disease in dyspepsia. Digestion. 1987;37(Suppl 1):14-17. [CrossRef]
20.Majeed M, Majeed S, Nagabhushanam K, et al. Evaluation of the
safety and efficacy of a multienzyme complex in patients with functional dyspepsia: a randomized, double-blind, placebo-controlled
study. J Med Food. 2018;21(11):1120-1128. [CrossRef]
21. Soytürk M, Bengi G, Oguz D, et al. Turkish gastroenterology association pancreas study group, chronic pancreatitis committee.
Chronic pancreatitis consensus report. Turk J Gastroenterol.
2020;31(Suppl 1):S1-S41. [CrossRef]
22.Tahtaci M, Koseoglu H, Alisik M, et al. Association of low fecal
elastase-1 and non-ulcer dyspepsia. J Clin Med. 2018;7(6):155.
[CrossRef]
23.Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J
Med. 2002;347(15):1175-1186. [CrossRef]
24.Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter
pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-429. [CrossRef]
25.Cindoruk M, Akalin S, Doğan Ü, et al. Prevalence of Helicobacter
pylori in patients with or without dyspepsia and comparison of different methods in the diagnosis of Helicobacter pylori. Turk J Gastroenterol. 1996;7(3):233-236.
26.Suzuki H, Moayyedi P. Helicobacter pylori infection in functional
dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10(3):168-174.
[CrossRef]
27.Çınar K, Soykan I, Özden A. The effect of Helicobacter pylori
eradication in patients with functional dyspepsia: assessment of different diagnostic tests. Turk J Gastroenterol. 2004;15(3):159-163.
28.Tack J, Talley NJ. Functional dyspepsia—symptoms, definitions
and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol.
2013;10(3):134-141. [CrossRef]
29.Piciucchi M, Capurso G, Archibugi L, Delle Fave MM, Capasso M,
Delle Fave G. Exocrine pancreatic insufficiency in diabetic patients:
prevalence, mechanisms, and treatment. Int J Endocrinol.
2015;2015:595649. [CrossRef]
30.Demir K, Karaca C, Ahishali E, et al. A cross-sectional study to
assess the prevalence of pancreatic exocrine insufficiency among
diabetes mellitus patients in Turkey. Pancreas. 2016;45(7):e39-e40.
[CrossRef]